TY - JOUR
T1 - Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1
AU - Whitaker, Jennifer A.
AU - Rouphael, Nadine G.
AU - Edupuganti, Srilatha
AU - Lai, Lilin
AU - Mulligan, Mark J.
N1 - Funding Information:
The authors received support from the following NIH grants: the Atlanta Clinical and Translational Science Institute ( UL1RR025008 [to JAW and NGR], KL2RR025009 or TL1 RR025010 [to NGR]), U19 AI090023-01 (to NGR, LL, and MJM), U01AI69418 (to NGR, SE, and MJM), NO1 A180005 (to NGR, SE, LL, and MJM), AI50409-07 (to LL and MJM), and AI074492, AI068614, and AI05726 (to MJM).
PY - 2012/12
Y1 - 2012/12
N2 - HIV and hepatitis B virus co-infection leads to substantially increased morbidity and mortality compared with either infection alone. Immunisation with hepatitis B virus vaccine is the most effective way to prevent the infection in people with HIV; however, these patients have decreased vaccine responses and a short duration of protection compared with immunocompetent individuals. Control of HIV replication with highly active antiretroviral therapy and increased CD4 cell counts are associated with improved immune responses to hepatitis B vaccination. New vaccination strategies, such as increased vaccine dose, use of the intradermal route, and addition of adjuvants, could improve response rates in adults with HIV.
AB - HIV and hepatitis B virus co-infection leads to substantially increased morbidity and mortality compared with either infection alone. Immunisation with hepatitis B virus vaccine is the most effective way to prevent the infection in people with HIV; however, these patients have decreased vaccine responses and a short duration of protection compared with immunocompetent individuals. Control of HIV replication with highly active antiretroviral therapy and increased CD4 cell counts are associated with improved immune responses to hepatitis B vaccination. New vaccination strategies, such as increased vaccine dose, use of the intradermal route, and addition of adjuvants, could improve response rates in adults with HIV.
UR - http://www.scopus.com/inward/record.url?scp=84869770264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869770264&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(12)70243-8
DO - 10.1016/S1473-3099(12)70243-8
M3 - Review article
C2 - 23174382
AN - SCOPUS:84869770264
SN - 1473-3099
VL - 12
SP - 966
EP - 976
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 12
ER -